ProstaScintρ scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients

Prostate

Volumn 37, Issue 4, 1998, Pages 261-269

  Elgamal, Abdel Aziz A ^a   Troychak, Michael J ^b   Murphy, Gerald P ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b NORTHWEST HOSPITAL   (United States)

Author keywords

Prostate cancer; ProstaScint scan; radioimmune scintigraphy; recurrence after prostatectomy, radiation therapy, and hormone therapy; prostate specific antigen; prostate specific membrane antigen

Indexed keywords

HORMONE; INDIUM CHLORIDE IN 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E11; PENTETIC ACID; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; INDIUM;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; EVALUATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSTATE; PROSTATE TUMOR; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; EVALUATION STUDIES; HORMONES; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031597381     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(19981201)37:4<261::aid-pros8>3.0.co;2-%23     Document Type: Article

References (29)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
2. Okada K, Yoshida O, Paulson DF, Rutishauser G: Lymph node staging in potentially curable prostatic carcinoma. EORTC Genitourinary Group Monogr 1988;5:221-225.
3. Tempany CM, Zhou X, Zerhouni EA, Rifkin MD, Quint LE, Piccoli CW, Ellis JH, McNeil BJ: Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994;192:47-54.
4. Haseman MK, Reed NL, Rosenthal SA: Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Clin Nucl Med 1996;21:704-713.
5. Murphy GP, Troychak MJ, Cobb OE, Bowes VA, Kenny RJ, Barren RJ, Kenny GM, Ragde H, Holmes EH, Wolfert R: Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Prostate 1997;33:141-146.
6. Rorvik J, Halvorsen OJ, Albreksten G, Haukaas S: Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol 1998;32:116-119.
7. Kramer S, Gorich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, Brambs H-J, Sokiranski R: Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997;70:995-999.
8. Fowler JE, Brooks J, Pandey P, Seaver LE: Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153:1011-1014.
9. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
10. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-241.
11. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, Purnell G, Harwood SJ: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 1992;10:45-54.
12. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV: Immunoscintigraphy in patients with colorectal, ovarian and prostate cancer. Cancer [Suppl] 1993;72:3453-3462.
13. 111indium-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-1955.
14. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
15. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL: Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients. Prostate 1997;33:281-285.
16. Burgers JK, Hinkle GH, Haseman MK: Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;13:103-112.
17. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159:2041-2047.
18. Chengazi VU, Feneley MR, Ellison D, Stalteri M, Granowski A, Granowska M, Nimmon CC, Mather SJ, Kirby RS, Britton KE: Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). J Nucl Med 1997;38:675-682.
19. Hinkle GH, Burgers JK, Olsen JO, Williams BS, Lamartice RA, Barth RF, Rogers B, Maguire RT: Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. J Nucl Med 1998;39:650-652.
20. Levesque PE, Nieh PT, Zinman EN, Seldin DW, Libertino JA: Radiolabeled monoclonal antibody indium 111-labeled CYT-365 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51:978-984.
21. Polascik TJ, Gurganus RT, Partin AW, Rogers B, Maguire R, Manyak MJ: Comparison of staging algorithms and a monoclonal antibody scan (ProstaScint) to predict lymph node involvement in high-risk prostate cancer [abstract]. J Urol 1998;159:289.
22. Ulchaker J, Klein E, Zippe C, Levin H, Neumann D, Ward M: Indium111 capromab monoclonal antibody: Utility in differentiating local versus distant relapse after radical prostatectomy [abstract]. J Urol 1997;157:205.
23. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B: Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint®) in detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759-767.
24. Elgamal AA, Petrovich Z, Van Poppel H, Baert E: The role of prostate specific antigen in the management of prostate cancer. In Petrovich Z, Baert E, Brady LW (eds): "Carcinoma of the Prostate: Innovations in Management," New York: Springer, 1996:179-196.
25. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
26. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298.
27. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR: The National Cancer Database report on prostate cancer following the peak in incidence rates in the United States. Cancer 1998;83:1679-1684.
28. Varkarakis MJ, Murphy GP, Nelson CMK, Chehval M, Moore RH, Flocks RH: Lymph node involvement in prostatic carcinoma. Urol Clin North Am 1975;2:197-212.
29. Saitoh H, Yoshida K-I, Uchijima Y, Kobayashi N, Suwata J, Kamata S: Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990;65:1843-1846.